Comparative Pharmacology
Head-to-head clinical analysis: GRISACTIN versus KETOZOLE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GRISACTIN versus KETOZOLE.
GRISACTIN vs KETOZOLE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Binds to microtubules and disrupts mitotic spindle formation, inhibiting fungal cell division.
Ketoconazole is an imidazole antifungal agent that inhibits fungal cytochrome P450 14α-demethylase, thereby blocking the conversion of lanosterol to ergosterol, a key component of the fungal cell membrane. This leads to increased membrane permeability and cell death.
500 mg orally once daily or 250 mg orally twice daily for dermatophyte infections.
200 mg orally once daily with food.
None Documented
None Documented
Terminal elimination half-life: 9–24 hours (mean ~14 hours). Clinical context: Steady-state achieved in 3–5 days; once-daily dosing is effective due to prolonged half-life.
Terminal elimination half-life is approximately 2 hours (range 1.5–3.5 hours). Clinically, duration of antifungal effect extends beyond plasma half-life due to persistent tissue levels.
Renal: <1% as intact drug; fecal: >99% as metabolites (mainly 6-demethylgriseofulvin glucuronide) via bile; negligible biliary excretion of parent compound.
Primarily hepatic metabolism; renal excretion of unchanged drug <1%. Biliary/fecal excretion accounts for ~20-35% of metabolites.
Category C
Category C
Antifungal
Antifungal